THERADIAG

Combined General Meeting of May 14, 2020 - Seite 3

In addition, the French National Authority for Health (HAS) confirmed on May 1, 2020, the validity of the approach of serological tests in ELISA format, such as those developed by Theradiag.

Participation in new Covid-19 clinical trials

Meanwhile, Theradiag continues to participate in clinical evaluations of the bioavailability to help evaluate the bioavailability (dosage) of biotherapies used in Covid-19 treatment candidates, in particular Tocilizumab.

Theradiag reminds that the results of these tests are not published, and that work relating to serology tests, although well under way, currently only represents a non-recurring activity. The Company does not have sufficient information to assess the potential impact of the clinical results of these evaluations, or to measure at this stage a potential effect of its “Serology Test” activities. Therefore, the Company confirms that it has not, for the time being, recorded in its forecasts any potential effect of these activities on its 2020 sales.

This initiative once again confirms the major role played by Theradiag, and its leading position in the field of biotherapy monitoring.

The Company will continue to keep the market and its stakeholders informed of any progress made in this regard as soon as it is relevant.

Disposal of Theradiag shares by HOB BIOTECH GROUP CORP. LTD.

The Company can confirm that HOB BIOTECH GROUP CORP. LTD. has informed it that it sold all of its Theradiag shares, as published by the French Financial Markets Authority (AMF) on May 7, 2020.

***

Financial calendar:
- Annual General Meeting convened for a second time, on June 25, 2020
- H1 2020 revenue, Tuesday, July 21, 2020
- H1 2020 results, Monday, September 21, 2020

About Theradiag
Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.

Theradiag pioneered “theranostics” testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, theranostics aims to help clinicians set up “customized treatment” for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2019, the Company posted revenue of €9.6 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan. For more information about Theradiag, please visit our website: www.theradiag.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005671/en/